Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
Leitner T; Shumilov E; Schwitlick C; Koch R; Hamm F; Högner M; Bassermann F; Weisel K; Einsele H; Kortüm M; Rasche L; Görner M; Wegehenkel K; Knop S; Krönke J; Nogai A; König IR; Vens M; Horn K; vo BN; Khandanpour C
Research article (journal) | Peer reviewedDetails about the publication
Journal: Frontiers in Hematology
Volume: 3
Status: Published
Release year: 2024
Language in which the publication is written: English
Link to the full text: https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2024.1436845/pdf
Keywords: isatuximab,newly diagnosed multiple myeloma,clinical trial,MRD,personalized therapy,high-dose melphalan,autologous stem cell transfusion
Authors from the University of Münster
| Koch, Raphael | Institute of Biostatistics and Clinical Research (IBKF) |